文献速递胃肠动力与功能性疾病

系统综述与Meta分析:美沙拉秦治疗肠易激综合征的疗效

Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-02-27

该系统综述与Meta分析纳入8项随机对照试验共820例肠易激综合征患者,评估美沙拉秦的疗效与安全性。美沙拉秦对整体肠易激综合征症状的改善优于安慰剂(未改善的相对风险为0.86,95%CI 0.79-0.95),但对腹痛或排便习惯或排便频率无显著效果;腹泻型肠易激综合征亚组显示整体症状获益(相对风险0.88,95%CI 0.79-0.99)。不良事件发生率未高于安慰剂(相对风险1.20,95%CI 0.89-1.63),但仅5项试验报告了不良事件。证据质量低。

要点

  • 美沙拉秦对整体肠易激综合征症状的改善优于安慰剂,需治疗人数为10(95%CI 6-27)。
  • 美沙拉秦对腹痛或排便习惯或排便频率无显著效果。
  • 腹泻型肠易激综合征亚组整体症状获益(相对风险0.88,95%CI 0.79-0.99),证据质量低。

核心结论

  • 美沙拉秦可能对肠易激综合征整体症状有适度疗效,尤其是腹泻型肠易激综合征,但证据质量低。
  • 需要足够把握度的高质量随机对照试验进一步研究美沙拉秦在肠易激综合征中的作用。

研究设计与样本

  • 系统综述与Meta分析,检索截至2022年9月14日的医学文献,纳入8项随机对照试验共820例肠易激综合征患者。
  • 采用随机效应模型合并数据,疗效与安全性以合并相对风险及95%置信区间报告。

主要发现

  • 美沙拉秦对整体肠易激综合征症状的改善优于安慰剂(未改善的相对风险0.86,95%CI 0.79-0.95;需治疗人数10,95%CI 6-27)。
  • 美沙拉秦对腹痛或排便习惯或排便频率无显著效果。
  • 腹泻型肠易激综合征亚组整体症状获益(相对风险0.88,95%CI 0.79-0.99),其他主要排便习惯类型及感染后肠易激综合征患者未见获益。
  • 美沙拉秦不良事件发生率未高于安慰剂(相对风险1.20,95%CI 0.89-1.63),但仅5项试验报告了不良事件。

局限性

  • 证据质量低。
  • 仅5项试验报告了不良事件。
  • 需要足够把握度的高质量随机对照试验进一步研究美沙拉秦在肠易激综合征中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Some patients with irritable bowel syndrome (IBS) demonstrate low-grade inflammation in the intestine. Mesalamine, which has anti-inflammatory effects, may be an efficacious treatment for IBS, but studies are conflicting. We conducted a systematic review and meta-analysis to assess efficacy and safety of mesalamine in IBS. METHODS: We searched the medical literature up to September 14, 2022, to identify randomized controlled trials (RCTs) of mesalamine in IBS. We judged efficacy and safety using dichotomous assessments of effect on global IBS symptoms, abdominal pain, bowel habit or stool frequency, and occurrence of any adverse event. We pooled data using a random effects model, with efficacy and safety reported as pooled relative risks (RRs) with 95% confidence intervals (CIs). RESULTS: We identified 8 eligible RCTs (820 patients). Mesalamine was more efficacious than placebo for global IBS symptoms (RR of global symptoms not improving, 0.86; 95% CI, 0.79-0.95; number needed to treat = 10; 95% CI, 6-27), but not for abdominal pain or bowel habit or stool frequency. Subgroup analyses demonstrated efficacy of mesalamine in IBS with diarrhea for global IBS symptoms (RR, 0.88; 95% CI, 0.79-0.99), but not patients with other predominant bowel habits or those with post-infection IBS. Adverse event rates were no higher with mesalamine (RR, 1.20; 95% CI, 0.89-1.63) but were reported in only 5 trials. CONCLUSIONS: Mesalamine may be modestly efficacious for global symptoms in IBS, particularly IBS with diarrhea, but quality of evidence was low. Adequately powered high quality RCTs of mesalamine in IBS are needed.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Goodoory VC, Tuteja AK, Black CJ, et al. Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2023. PMID: 36858143. doi:10.1016/j.cgh.2023.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。